Guidelines for Managing Allergic Bronchopulmonary Aspergillosis (ABPA)

Initial Assessment and Classification

• The European Respiratory Society recommends classifying ABPA as either ABPA with bronchiectasis (ABPA-B) or ABPA without bronchiectasis (ABPA-S) to guide treatment decisions 1
• Asymptomatic ABPA patients should not receive systemic therapy, as recommended by the European Respiratory Society 2
• ABPA-S should be managed like asthma without specific ABPA treatment unless there is poor asthma control or recurrent exacerbations despite optimal asthma management, according to the European Respiratory Society 2

First-Line Treatment Options for Acute ABPA

• The European Respiratory Society recommends oral prednisolone (0.5 mg/kg/day for 2-4 weeks, tapered over 4 months) as a first-line treatment for acute ABPA 3
• The European Respiratory Society recommends oral itraconazole for 4 months as a first-line treatment for acute ABPA, especially when systemic glucocorticoids are contraindicated 3
• The European Respiratory Society suggests monitoring for side effects of oral corticosteroids, including osteopenia, and correcting vitamin D deficiency to minimize this risk 1

Management of ABPA Exacerbations

• The European Respiratory Society reports that ABPA exacerbations occur in approximately 50% of patients after treatment cessation 3
• The European Respiratory Society defines ABPA exacerbations as sustained worsening (≥2 weeks) of clinical symptoms or new infiltrates on chest imaging, and an increase in serum total IgE by ≥50% above the "new baseline" IgE during clinical stability 3
• The European Respiratory Society recommends treating acute ABPA exacerbations with oral prednisolone or itraconazole, and considering combination therapy with oral prednisolone and itraconazole for recurrent exacerbations 3

Monitoring Treatment Response

• The European Respiratory Society recommends monitoring response to treatment after 8-12 weeks using clinical symptoms, serum total IgE levels, and chest radiographs 3
• The European Respiratory Society defines a good response to treatment as significant improvement in symptoms (≥50% improvement on Likert scale), improvement on imaging, and at least a 20% reduction in serum total IgE levels 3

Special Considerations

• The European Respiratory Society suggests differentiating between ABPA exacerbations, asthma exacerbations, and infective exacerbations of bronchiectasis using chest radiographs, serum total IgE, and sputum bacterial cultures 3
• The European Respiratory Society recommends considering combination therapy with prednisolone and itraconazole for patients with blood eosinophil count ≥1000 cells/μL and extensive bronchiectasis (≥10 segments) 4

Management of Allergic Bronchopulmonary Aspergillosis (ABPA)

Treatment-Dependent ABPA

• Long-term itraconazole is the preferred maintenance option, reducing oral glucocorticoid dose, sputum eosinophil count, and ABPA exacerbations, with therapeutic drug monitoring being mandatory, as recommended by the European Respiratory Society 5, 6
• Nebulized amphotericin B, liposomal formulation 25 mg weekly, significantly prolongs time-to-first exacerbation, according to the European Respiratory Society 5, 6
• Biological agents, such as omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab, have been used successfully for maintenance therapy, with omalizumab having the most evidence, reducing exacerbations, hospitalizations, improving lung function, and decreasing oral steroid requirements, as recommended by the European Respiratory Society 5, 6

Remission Management

• During stable disease, focus on underlying conditions, managing asthma and bronchiectasis per existing guidelines, monitoring with clinical review, serum total IgE, and lung function tests every 3-6 months for the first year, then every 6-12 months, as recommended by the European Respiratory Society 5, 6, 7
• Periodic assessments determine the ongoing need for antifungal azoles or biological agents, with a level of certainty of 100%, according to the European Respiratory Society 5, 6

Advanced ABPA with Extensive Bronchiectasis

• Nebulized hypertonic saline (3-7%, 4-5 mL) reduces sputum viscosity and eases mucus plug expectoration, preceding with nebulized salbutamol to minimize bronchospasm risk, and administering the first dose under supervision, as recommended by the European Respiratory Society 5, 7
• Nebulized antibiotics and long-term azithromycin are considered for patients with frequent infective exacerbations, with a critical caveat that azithromycin with itraconazole can cause QTc prolongation, according to the European Respiratory Society 5, 7
• Long-term oxygen therapy (LTOT) is recommended for resting hypoxemia (PaO2 ≤55 mmHg), reducing pulmonary hypertension, but has no role in mild hypoxemia (PaO2 >55 mmHg at rest), as recommended by the European Respiratory Society 5, 7
• The International Society for Heart and Lung Transplantation criteria are used for transplant referral, according to the European Respiratory Society 7

Remission Management of Allergic Bronchopulmonary Aspergillosis (ABPA)

Monitoring Schedule

• Patients in remission should undergo clinical review, serum total IgE measurement, and lung‑function testing every 3–6 months during the first year and thereafter every 6–12 months for lifelong surveillance. (European Respiratory Society) [8][9]10

Underlying Respiratory Disease Management

• Asthma and bronchiectasis must be treated aggressively according to existing asthma and bronchiectasis guidelines, using inhaled corticosteroids, long‑acting bronchodilators, nebulized saline, and antibiotics when indicated. (European Respiratory Society) [8][9]

Maintenance Therapy to Prolong Remission

Antifungal Therapy

• Long‑term itraconazole (consensus 100 %) reduces oral glucocorticoid needs, sputum eosinophil counts, and ABPA exacerbations. (European Respiratory Society) [9][8]
• Caution: concomitant azithromycin may cause QTc prolongation; ECG monitoring is required. (European Respiratory Society) [8][9]

Inhaled Antifungal Therapy

• Nebulized liposomal amphotericin B 25 mg weekly significantly prolongs time‑to‑first exacerbation; the NEBULAMB trial (139 patients) demonstrated a longer exacerbation‑free interval versus placebo. (European Respiratory Society) [10][8]9

Biologic Agents

• Omalizumab reduces ABPA exacerbations and hospitalizations, improves lung function, and lowers oral steroid requirements. (European Respiratory Society) [8][9]
• Dupilumab (anti‑IL‑4Rα) shows emerging superiority over other biologics for treatment‑dependent disease. (European Respiratory Society) [8][9]

Low‑Dose Glucocorticoids

• Continuous low‑dose oral glucocorticoids are reserved as a last‑resort option when other maintenance strategies fail. (European Respiratory Society) [8][9]

Periodic Reassessment of Maintenance Therapy

• For patients achieving remission on antifungal azoles or biologics, periodic reassessment (consensus 100 %) determines the ongoing need for therapy; duration should be individualized based on clinical response. (European Respiratory Society) [9][10]

Management of Advanced Bronchiectasis Complications

Airway Clearance

• Both interventions follow the same citation sources. (European Respiratory Society) [8][9]

Infection Control

• Nebulized antibiotics and long‑term azithromycin are recommended for patients with frequent infective bronchiectasis exacerbations. (European Respiratory Society) [8][9]

Oxygen Therapy for Respiratory Failure

• Long‑term oxygen therapy (LTOT) is indicated for resting hypoxemia (PaO₂ ≤ 55 mm Hg) and improves survival by reducing pulmonary hypertension. (European Respiratory Society) [8][9]
• LTOT is not indicated for mild hypoxemia (PaO₂ > 55 mm Hg) or isolated nocturnal desaturation. (European Respiratory Society) [8][9]

Vaccination Recommendations

• Patients with chronic or allergic aspergillosis have a reduced response to the 23‑valent pneumococcal polysaccharide vaccine. (European Respiratory Society) [8][9]
• Influenza and pneumococcal vaccines should be administered before initiating systemic glucocorticoids, or delayed until the underlying condition is better controlled. (European Respiratory Society) [8][9]

Transplant Referral Criteria

• Advanced ABPA patients should be evaluated for lung transplantation using the International Society for Heart and Lung Transplantation (ISHLT) criteria. (European Respiratory Society) 9

Safety Considerations

• When combining azithromycin with itraconazole, monitor the QTc interval with an ECG to mitigate the risk of prolongation. (European Respiratory Society) [8][9]